title: Stem cells and the frontiers of neonatology.
abstract: The aim of the most recent studies on regenerative medicine was to focus on capability of stem cells deriving not only from haematopoietic system, but also from other organ and tissues, to regenerate damaged tissues. Stem cells derived from foetal annexes such as cord blood, placenta and amniotic fluid can be currently used in the effort to treat prenatally diagnosed genetic diseases. Cells derived from cord blood have been used since 1988 as an alternative source to realize stem cell transplantation. Compared with bone marrow, cord blood has shown the advantages of quick availability, less risk of GHVD, together with higher compatibility rates, and less risk of infections. Mesenchymal stem cells (MSCs) are multi-potent stem cells able to differentiate into different lineages, including osteocytes, chondrocytes, and adipocytes. Because of their trafficking capacity to injured tissues, clinical trials have been started evaluating the use of MSCs in the treatment of metabolic diseases like Hurler syndrome and metachromatic leukodystrophy, or Osteogenesis Imperfecta. MSCs were initially identified in adult bone marrow (BM-MSC), but cells resembling BM-MSCs have also been found in other tissues, both adult (peripheral blood, synovial membrane) and foetal (peripheral blood, liver, spleen, placenta, umbilical cord, and amniotic membrane). BM-MSCs have been widely used in clinical applications, as for cell-based therapy of Osteogenesis Imperfecta and metabolic diseases. In addition, human multi-potent MSCs present in second-trimester amniotic fluids may be a good target for prenatal gene therapy because of their expandability, their ability to differentiate into multiple lineages and their high transduction efficiency.
authors.affiliation: Department of Pediatric Onco-haematology and BMT Unit, Children's Hospital, Spedali Civili, Brescia, Italy.
authors.forename: Arnalda
authors.initials: A
authors.lastname: Lanfranchi
authors.forename: Fulvio
authors.initials: F
authors.lastname: Porta
authors.forename: Gaetano
authors.initials: G
authors.lastname: Chirico
mesh_terms: D000653:Amniotic Fluid / Q000166:cytology*; D036101:Cord Blood Stem Cell Transplantation; D015925:Cryopreservation; D005312:Fetal Blood / Q000166:cytology*; D015316:Genetic Therapy; D006801:Humans; D045164:Mesenchymal Stem Cell Transplantation; D059630:Mesenchymal Stem Cells / Q000502:physiology*; D009359:Neonatology / Q000639:trends*